Skip to content

Procedural Oxygen Mask vs. High-flow Nasal Cannula for Hypoxemia Prevention During ERCP

Comparison of Procedural Oxygen Mask vs. High-flow Nasal Cannula for Hypoxemia Prevention During Endoscopic Retrograde Cholangiopancreatography (ERCP): A Randomized Parallel-GroupTrial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06817603
Enrollment
150
Registered
2025-02-10
Start date
2025-03-07
Completion date
2025-06-03
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxemia

Keywords

Hypoxemia, Endoscopic Retrograde Cholangiopancreatography, Airway Management

Brief summary

Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging procedure that visualizes the drainage ducts of the pancreas, gallbladder, and liver through the use of a duodenoscope and contrast media. By endoscopically identifying the ampulla of Vater, the common bile duct is cannulated. ERCP is also frequently utilized for therapeutic interventions, such as endoscopic sphincterotomy, bile duct stone extraction, stent placement in malignant and benign biliary strictures, and biopsy collection, thus playing a critical role in both the diagnosis and treatment of pancreatobiliary disorders. ERCP, being more invasive than routine upper endoscopies or colonoscopies, typically necessitates deeper levels of sedation. The procedure is performed in the prone, modified prone, or lateral decubitus position, which increases the risk of hypoxemia and hypoventilation due to upper airway obstruction. Furthermore, endoscopic instruments inserted through the oral cavity limit anesthesiologists' access to the patient's airway, thereby restricting ventilation support during gastrointestinal endoscopy. Ensuring airway stability during sedation is paramount for patient safety and procedural efficacy. Currently, a range of devices, including traditional nasal cannulas, high-flow oxygen masks, and procedural oxygen masks, are employed to provide oxygen support throughout the procedure. The existing literature includes randomized controlled trials and systematic reviews aimed at preventing hypoxemia during ERCP. Through this study, investigators aim to make a novel contribution to the literature by assessing the effectiveness of a recently introduced procedural oxygen mask.

Detailed description

This study aims to compare the efficacy of two oxygen delivery methods-High-Flow Nasal Cannula (HFNC) and Procedural Oxygen Mask (POM)-in preventing hypoxemia during Endoscopic Retrograde Cholangiopancreatography (ERCP). Designed as a randomized, parallel-group, prospective study, participants were assigned to two groups, Group H (HFNC) and Group P (POM), in a 1:1 ratio using computer-assisted random allocation. However, due to the visible differences between the oxygen delivery devices, neither healthcare providers nor patients could be blinded to the randomization. The study was planned to include 134 patients (67 per group) with a 95% confidence level (1-α) and 90% test power (1-β). To account for an anticipated 10% dropout rate, the total sample size was set at 150 patients. Throughout the ERCP procedure, all patients will be monitored using pulse oximetry, electrocardiography (ECG), and non-invasive blood pressure monitoring. Capnography will be applied in both groups, and necessary interventions will be carried out by anesthesia specialists if a patient's oxygen saturation falls below 90%. All interventions and events will be meticulously documented. Following the procedure, patients will be monitored in the post-anesthesia care unit (PACU), and those with a Modifiye Alderete score of 10 will be discharged. The FiO2 will be maintained constant throughout the procedure. Patients will initially receive midazolam at a dose of 0.02 mg/kg, followed by 0.5 mg/kg of ketamine. To ensure adequate sedation, propofol will be administered as an initial bolus dose of 0.5-1.0 mg/kg, with additional boluses of 0.25-0.5 mg/kg every 1-3 minutes as needed to maintain the target sedation level. The target sedation depth will be 3-4 on the Ramsay Sedation Scale (RSS), and this level will be maintained throughout the procedure. Upon completion, patients will be awakened using verbal and tactile stimuli. Once their RSS reaches 2, they will be transferred to the Post-Anesthesia Care Unit (PACU). Patients will be discharged from the PACU upon achieving a Modified Aldrete Score (MAS) of 10. Vital signs, procedure durations, and dosages of medications used for each patient will be meticulously recorded. All anesthesia-related decisions during the procedure will be made by the supervising anesthesia specialist.

Interventions

Procedural Oxygen Mask will be used

DEVICEHigh-Flow Nasal Cannula

High-Flow Nasal Cannula (HFNC) will be used.

Sponsors

Kocaeli City Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-75 years * American Society of Anesthesiologists (ASA) classification of 1-2-3 * Patients scheduled for ERCP at Kocaeli City Hospital Endoscopy Unit

Exclusion criteria

* Refused to participate in the study * Had an allergy to ketamine, propofol, or midazolam * Had a BMI \>30 kg/m² * Were pregnant or in the postpartum period * Had a STOP-BANG score ≥3 * Had a history of intubation within the past 3 months * Had a history of lower respiratory tract infection within the past 3 months * Had a history of intensive care unit (ICU) admission within the past 3 months * Had a tracheostomy or a history of tracheostomy placement * Were oxygen-dependent * Had lung cancer or a history of lung surgery * Had asthma, COPD, or interstitial lung disease

Design outcomes

Primary

MeasureTime frameDescription
incidence of hypoxemiaContinuous SpO2 monitoring will be performed throughout the ERCP procedureThe incidence of hypoxemia during sedation (defined as SpO2 \< 90%). SpO₂ will be continuously measured using a pulse oximeter (GE Healthcare) to monitor and record oxygen saturation levels throughout sedation.

Secondary

MeasureTime frameDescription
Duration of hypoxemiaContinuous SpO2 monitoring will be performed throughout the ERCP procedureDefined as the time taken to reach SpO2 ≥ 90%. SpO₂ will be continuously measured using a pulse oximeter (GE Healthcare) to monitor and record oxygen saturation levels throughout sedation.
Continuous SpO2 monitoring will be performed throughout the ERCP procedureContinuous SpO2 monitoring will be performed throughout the ERCP procedureMinimum SpO2 value observed during the procedure. SpO₂ will be continuously measured using a pulse oximeter (GE Healthcare) to monitor and record oxygen saturation levels throughout sedation.
Frequency of Chin Lift ManeuverInterventions related to airway management causing interruptions during the procedureThis outcome measure will assess the frequency of the chin lift maneuver performed during the procedure due to hypoxemia
Frequency of Jaw Thrust ManeuverInterventions related to airway management causing interruptions during the procedureThis outcome measure will assess the frequency of the Jaw Thrust maneuver performed during the procedure due to hypoxemia
Frequency of Mask VentilationInterventions related to airway management causing interruptions during the procedureThis outcome measure will assess the frequency of the Mask Ventilation performed during the procedure due to hypoxemia
Number of hypoxemia episodesContinuous SpO2 monitoring will be performed throughout the ERCP procedureAn episode was recorded when SpO2 dropped below 90% after reaching a level of SpO2 ≥ 90% for 30 seconds. SpO₂ will be continuously measured using a pulse oximeter (GE Healthcare) to monitor and record oxygen saturation levels throughout sedation.
Frequency of High-Flow Nasal Cannula or Procedural Oxygen Mask (POM) RepositioningInterventions related to airway management causing interruptions during the procedureThis outcome measure will assess the frequency of Frequency of High-Flow Nasal Cannula or Procedural Oxygen Mask (POM) Repositioning during the procedure due to hypoxemia
Other potential complicationsduring the procedureOther potential complications that may arise during the procedure (hypotension, hypertension, bradycardia, tachycardia, movements that hinder the procedure) (Hypotension is defined as a decrease in the patient's baseline systolic blood pressure of more than 20% or a drop below 90 mm Hg. Hypertension is defined as an increase in the patient's baseline systolic blood pressure of more than 20%. A heart rate below 60 beats per minute is considered bradycardia, while a rate above 100 beats per minute is classified as tachycardia)
Gastroenterologist satisfactionwith data reported immediately following the completion of the procedurea 10-point scoring system was used, where 0 indicates unmanageable, numerous interruptions or terminated procedure, and 10 indicates excellent sedation, no interruptions
Patient satisfaction related to anesthesiaData will be recorded until discharge from the PACU, which is expected to occur within up to 2 hours after the procedurePatient satisfaction related to anesthesia was assessed and recorded before discharge (a scale from 0 to 10 was used, where 0 means very poor, I would never undergo this procedure again, and 10 means excellent, I would undergo this procedure again in the same manner
Dry mouth/nose/throat:Data will be recorded until discharge from the PACU, which is expected to occur within up to 2 hours after the procedureBefore discharge, patients in the Post-Anesthesia Care Unit (PACU) will be assessed for dry mouth, nose, and throat
Frequency of Need for AspirationInterventions related to airway management causing interruptions during the procedureThis outcome measure will assess the frequency of need for aspiration performed during the procedure due to hypoxemia

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026